GLP-1

• People on GLP-1 drugs appear to do less physical activity: study

  Participants' daily steps decreased from about 5,047 to 4,487 per day. Moderate-to-vigorous physical activity also dropped, from 28 minutes a day to 22 minutes a day,

  Canada

  Jun 18
  
• Can GLP-1s lower some cancer risks? What new research suggests

  Currently, two generic versions of Ozempic and Wegovy are available for Canadians to purchase for patients who use it to treat diabetes or weight loss for a fraction of the cost.

  Health

  Jun 11
  
• Advertisement
• Novo Nordisk will slash Ozempic price for some, ‘aligning’ with generics

  Ozempic and Wegovy, both produced by Novo Nordisk, currently cost hundreds of dollars a month, depending on the dosage dispensed, in some cases more than $450.

  Health

  May 26
• Advertisement
• Generic semaglutide to hit Canadian pharmacies this week at lower cost

  Health Canada approved both Dr. Reddy's and Apotex's generic semaglutide — the active ingredient in brand-name Ozempic and Wegovy — about three weeks ago.

  Health

  May 20
• Canadians can now get Ozempic, Wegovy delivered to their homes. Here’s how

  Patients can receive the treatments at home for 'no additional cost' and will have the option of chatting with a pharmacist over the phone, Novo Nordisk said.

  Canada

  May 13
• Health Canada approves country’s 1st generic version of Ozempic

  The injectable semaglutide medication is manufactured by Dr. Reddy's Laboratories in India and is approved for the once-weekly treatment of Type 2 diabetes in adults.

  Health

  Apr 28
• U.S. FDA approves Eli Lilly’s GLP-1 oral weight-loss pill

  The U.S. FDA said the drug was approved within 50 days of the company filing for approval, one of the fastest approval times for any drug.

  Health

  Apr 1
• Could GLP-1 drugs help your mental health? New study finds a link

  Semaglutide, the active ingredient in GLP-1 drugs, was associated with a lower risk of worsening mental health, a study published in Lancet Psychiatry found.

  Health

  Mar 20
• Advertisement
• Novo Nordisk says generic Ozempic, Wegovy will slow sales in Canada

  Novo Nordisk says the expiration of its patents for some semaglutide GLP-1 drug treatments in markets like Canada will result in more generics and hurt sales.

  Health

  Feb 4
• Advertisement
• Health Canada approves 1st GLP-1 daily pill. Here’s who can take it

  The once-a-day semaglutide pill is approved for reducing the risk of heart disease and Type 2 diabetes, the company said in a statement Monday.

  Canada

  Jan 12